HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 14 PAGES: 48

More Info
									HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012




    HIV-Associated Lipodystrophy Syndrome – Pipeline
                     Review, H1 2012
                                                                                          Reference Code: GMDHC1712IDB
                                                                                            Publication Date: January 2012




HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012                           GMDHC1712IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
HIV-Associated Lipodystrophy Syndrome Overview .......................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome .......................................................................... 8
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies .......................................................... 10
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes ............................................ 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
HIV-Associated Lipodystrophy Syndrome Therapeutics – Products under Development by Companies ........................................ 16
HIV-Associated Lipodystrophy Syndrome Therapeutics – Products under Investigation by Universities/Institutes .......................... 17
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development ....................................................... 18
    Ark Therapeutics Group plc ......................................................................................................................................................... 18
    Zydus Cadila Healthcare Limited ................................................................................................................................................. 19
    Theratechnologies Inc. ................................................................................................................................................................ 20
HIV-Associated Lipodystrophy Syndrome – Therapeutics Assessment ........................................................................................... 21
    Assessment by Monotherapy Products ....................................................................................................................................... 21
    Assessment by Combination Products ........................................................................................................................................ 22
    Assessment by Route of Administration ...................................................................................................................................... 23
    Assessment by Molecule Type .................................................................................................................................................... 25
Drug Profiles..................................................................................................................................................................................... 27
    Tesamorelin - Drug Profile ........................................................................................................................................................... 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    ZYH1 - Drug Profile ..................................................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Pioglitazone + Leptin - Drug Profile ............................................................................................................................................. 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30
         R&D Progress ......................................................................................................................................................................... 30
    Recombinant Human Growth Hormone - Drug Profile................................................................................................................. 31
         Product Description................................................................................................................................................................. 31



HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012                                                                              GMDHC1712IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................... 31
        R&D Progress ......................................................................................................................................................................... 31
    Avandia - Drug Profile ................................................................................................................................................................. 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    Recombinant Human Growth Hormone + Rosiglitazone - Drug Profile ....................................................................................... 33
        Product Description................................................................................................................................................................. 33
        Mechanism of Action ............................................................................................................................................................... 33
        R&D Progress ......................................................................................................................................................................... 33
    Leptin - Drug Profile..................................................................................................................................................................... 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    EG005 - Drug Profile ................................................................................................................................................................... 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Recombinant IGF-I - Drug Profile ................................................................................................................................................ 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Eutrophill - Drug Profile ............................................................................................................................................................... 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progr
								
To top